Skip To Main Content
Robin Fields on Muck Rack

Robin Fields

Verified
New York
As seen in: ProPublica, CNN, MSN, Aol, CNBC, PBS, The Atlantic, Flipboard, Salon, Medscape, Military.com and
Global health reporter, ProPublica; formerly managing editor at ProPublica, cat servant
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Robin

Contact Robin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ProPublica Investigations You May Have Missed in 2025

|
By Kyle Hopkins Verified, Mary Hudetz Verified, Hannah K Bassett, Robin Fields Verified
| ProPublica Verified
Support fearless, independent journalism The story you just read was made possible by our readers. We hope it inspires you to support ProPublica, so we can continue producing investigations that shine a light on power, uncover the truth and drive real change. ProPublica is a nonprofit newsroom dedicated to nonpartisan, evidence-based journalism that holds power accountable.
Open in Who Shared Issue with article?

What a $2 million per dose gene therapy reveals about drug pricing

|
By Robin Fields Verified
| Salon Verified
Reporting Highlights A Record Price: The gene therapy Zolgensma helped children born with a fatal disease, spinal muscular atrophy, grow up to run and play. But the cost was stunning: $2 million per dose. Cashing In: While taxpayers and small charities funded the drug’s early development, executives, venture-capital backers and a pharma giant have reaped the profits.
Open in Who Shared View Duplicates (3) Issue with article?

What a $2 million per dose gene therapy reveals about drug pricing Original

|
By Robin Fields Verified
| CNN Verified
Breakthrough drugs like Zolgensma and other gene therapies are adding to the nation’s ballooning bill for prescription drugs, absorbed by all Americans in the form of rising insurance premiums and taxes for public programs like Medicaid. Owen Gent, special to ProPublica This story was originally published by ProPublica. ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive its biggest stories as soon as they’re published.
Open in Who Shared View Duplicates (3) Issue with article?
See all 137 licensed articles (139 Total)